Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 4/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2699779 | 1.00 | ALDH1A1 (0.41) | ALDH1A1GAAAURKARPS6KB1ANPEP | |
| SCHEMBL10002494 | 1.00 | ALDH1A1 (0.41) | ALDH1A1GAAAURKARPS6KB1ANPEP | |
| SCHEMBL4758031 | 1.00 | ALDH1A1 (0.41) | ALDH1A1GAAAURKARPS6KB1ANPEP | |
| SCHEMBL177088 | 1.00 | ALDH1A1 (0.41) | ALDH1A1GAAAURKARPS6KB1ANPEP | |
| SCHEMBL3092977 | 1.00 | ALDH1A1 (0.41) | ALDH1A1GAAAURKARPS6KB1ANPEP | |
| SCHEMBL3327022 | 0.83 | ALDH1A1 (0.41) | ALDH1A1GAANAMPTMEN1KMT2A | |
| SCHEMBL8410178 | 0.83 | ALDH1A1 (0.41) | ALDH1A1GAANAMPTMEN1KMT2A | |
| SCHEMBL8045772 | 0.83 | ALDH1A1 (0.41) | ALDH1A1GAANAMPTMEN1KMT2A | |
| SCHEMBL4283036 | 0.81 | ALDH1A1 (0.41) | ALDH1A1GAAANPEPKDM1AATM | |
| SCHEMBL562899 | 0.81 | KDM1A (0.42) | ALDH1A1GAAANPEPKDM1AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378096-B2 | Hexahydro-cycloheptapyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | claimed |
| EP-1937259-B1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-23 | — | — | EP | claimed |
| US-7790718-B2 | Tetrahydro-cyclopentyl pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-07 | — | — | US | claimed |
| US-20090197886-A1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-06 | — | — | US | claimed |
| US-7524964-B2 | Tetrahydrothiopyrano pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-28 | — | — | US | claimed |
| EP-1863479-B1 | TETRAHYDROTHIOPYRANO PYRAZOLE CANNABINOID MODULATORS CROSS REFERENCE TO RELATED APPLICATIONS | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-10 | — | — | EP | claimed |
| US-20080085899-A1 | TETRAHYDROTHIOPYRANO PYRAZOLE CANNABINOID MODULATORS | LIOTTA FINA | 2008-04-10 | — | — | US | claimed |
| US-20080070968-A1 | Hexahydro-Cycloheptapyrazole Cannabinoid Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-20 | — | — | US | claimed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070191362-A1 | Tetrahydro-cyclopentyl pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-16 | — | — | US | claimed |
| US-20070123578-A1 | Hexahydro-cycloheptapyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-31 | — | — | US | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| US-20060223798-A1 | Tetrahydrothiopyrano pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2006-10-05 | — | — | US | claimed |
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11214548-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20070123578-A1 | Hexahydro-cycloheptapyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-31 | — | — | US | disclosed |
| WO-2007035945-A1 | TETRAHYDRO-CYCLOPENTYL PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-29 | — | — | WO | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20060223798-A1 | Tetrahydrothiopyrano pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197886-A1 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | CNR2, CNR1, FAAH | ALDH1A1 1422/4885GAA 1716/4885AURKA 4538/4885 |
| US-20060223798-A1 | Tetrahydrothiopyrano pyrazole cannabinoid modulators | CNR1, CNR2, GPR18 | ALDH1A1 1724/4885GAA 3305/4885AURKA 4686/4885 |
| US-20080085899-A1 | TETRAHYDROTHIOPYRANO PYRAZOLE CANNABINOID MODULATORS | CNR1, CNR2, GPR18 | ALDH1A1 1724/4885GAA 3305/4885AURKA 4686/4885 |
| US-20070191362-A1 | Tetrahydro-cyclopentyl pyrazole cannabinoid modulators | CNR1, CNR2, GPR18 | ALDH1A1 2068/4885GAA 3989/4885AURKA 4568/4885 |
| US-20080070968-A1 | Hexahydro-Cycloheptapyrazole Cannabinoid Modulators | CNR2, CNR1, FAAH | ALDH1A1 1422/4885GAA 1716/4885AURKA 4538/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | ALDH1A1 1278/4885GAA 53/4885AURKA 1817/4885 |
| US-11746091-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | ALDH1A1 3623/4885GAA 3665/4885AURKA 2601/4885 |
| US-11214548-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | ALDH1A1 3623/4885GAA 3665/4885AURKA 2601/4885 |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | ALDH1A1 603/4885GAA 718/4885AURKA 3718/4885 |
| US-20070123578-A1 | Hexahydro-cycloheptapyrazole cannabinoid modulators | CNR2, CNR1, FAAH | ALDH1A1 1422/4885GAA 1716/4885AURKA 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.